Arsanis Inc (ASNS) Receives $14.25 Average PT from Brokerages
Arsanis Inc (NASDAQ:ASNS) has received an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $14.25.
ASNS has been the topic of several analyst reports. Zacks Investment Research upgraded Arsanis from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Tuesday, July 10th. Citigroup downgraded Arsanis from a “buy” rating to a “neutral” rating in a report on Monday, July 9th. Cowen downgraded Arsanis from an “outperform” rating to a “market perform” rating in a report on Monday, July 2nd. Finally, Piper Jaffray Companies decreased their price objective on Arsanis to $2.50 and set a “neutral” rating on the stock in a report on Monday, August 13th.
NASDAQ ASNS opened at $1.32 on Friday. Arsanis has a twelve month low of $1.31 and a twelve month high of $28.69. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 0.20.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in shares of Arsanis by 6.4% in the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock worth $5,663,000 after buying an additional 14,819 shares during the period. BlackRock Inc. increased its holdings in shares of Arsanis by 27.1% in the second quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock worth $812,000 after buying an additional 47,777 shares during the period. Granahan Investment Management Inc. MA purchased a new position in shares of Arsanis in the second quarter worth about $365,000. Northern Trust Corp purchased a new position in shares of Arsanis in the first quarter worth about $735,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Arsanis in the first quarter worth about $200,000. Hedge funds and other institutional investors own 68.70% of the company’s stock.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Featured Article: Find a Trading Strategy That Works
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.